Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALOX5 | P09917 | 2/20 | 0.63 |
| ▸ | BACE1 | P56817 | 1/20 | 0.54 |
| ▸ | ADORA1 | P30542 | 2/20 | 0.47 |
| ▸ | ADORA3 | P0DMS8 | 1/20 | 0.46 |
| ▸ | ADORA2A | P29274 | 1/20 | 0.46 |
| ▸ | GAA | P10253 | 6/20 | 0.44 |
| ▸ | TRIM24 | O15164 | 2/20 | 0.43 |
| ▸ | TRIM33 | Q9UPN9 | 2/20 | 0.43 |
| ▸ | TP53 | P04637 | 1/20 | 0.43 |
| ▸ | POLB | P06746 | 1/20 | 0.43 |
| ▸ | ALDH1A1 | P00352 | 5/20 | 0.42 |
| ▸ | MAPT | P10636 | 3/20 | 0.42 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.42 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.42 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.42 |
| ▸ | KDM4E | B2RXH2 | 3/20 | 0.41 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.41 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.41 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.41 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1967579 | 0.99 | ALOX5 (0.65) | ALOX5BACE1ADORA1ADORA3ADORA2A | |
| SCHEMBL2992223 | 0.86 | ALOX5 (0.63) | ALOX5BACE1ADORA1GAATRIM24 | |
| SCHEMBL5127843 | 0.85 | ALOX5 (0.65) | ALOX5BACE1ADORA1GAATRIM24 | |
| SCHEMBL5168420 | 0.84 | ALOX5 (0.66) | ALOX5BACE1ADORA1TRIM24TRIM33 | |
| SCHEMBL15152567 | 0.82 | ALOX5 (0.47) | ALOX5BACE1ADORA1ADORA3ADORA2A | |
| SCHEMBL1970474 | 0.81 | ALDH1A1 (0.63) | ALOX5BACE1ADORA1GAATRIM24 | |
| SCHEMBL1967241 | 0.81 | SALL4 (0.47) | ALOX5BACE1ADORA1ADORA3ADORA2A | |
| SCHEMBL1965252 | 0.80 | ADORA1 (0.64) | ALOX5BACE1ADORA1GAATRIM24 | |
| SCHEMBL1966867 | 0.79 | ALDH1A1 (0.67) | ALOX5BACE1ADORA1GAATRIM24 | |
| SCHEMBL5165713 | 0.78 | ALOX5 (0.78) | ALOX5BACE1ADORA1GAAALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 72 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11697812-B2 | Methods and compositions for the specific inhibition of transthyretin (TTR) by double-stranded RNA | DICERNA PHARMACEUTICALS, INC. (US) | 2023-07-11 | — | — | US | claimed |
| US-20230069235-A1 | METHODS AND COMPOSITIONS FOR THE SPECIFIC INHIBITION OF ALPHA-1 ANTITRYPSIN BY DOUBLE-STRANDED RNA | NOVO NORDISK A/S (DK) | 2023-03-02 | — | — | US | claimed |
| US-11359203-B2 | Therapeutic inhibition of lactate dehydrogenase and agents therefor | DICERNA PHARMACEUTICALS, INC. (US) | 2022-06-14 | — | — | US | claimed |
| EP-4716529-A2 | COMPOUNDS THAT RE-ACTIVATE MUTANT P53 | Institute For Cancer Research d/b/a The Research Institute of Fox Chase Cancer Center (US) | 2026-04-01 | — | — | EP | disclosed |
| US-12552882-B2 | Polymeric disinfectants and uses thereof | TECHNION RESEARCH & DEVELOPMENT FOUNDATION LTD. (IL) | 2026-02-17 | — | — | US | disclosed |
| US-20250387582-A1 | PATIENT INTERFACE AND COMPONENT PARTS | FISHER & PAYKEL HEALTHCARE LTD (NZ) | 2025-12-25 | — | — | US | disclosed |
| US-12499971-B2 | Systematic screening and mapping of regulatory elements in non-coding genomic regions, methods, compositions, and applications thereof | THE BROAD INSTITUTE, INC. (US) | 2025-12-16 | — | — | US | disclosed |
| EP-4237493-B1 | POLYMERIC DISINFECTANTS AND USES THEREOF | TECHNION RES & DEV FOUNDATION (IL) | 2025-12-10 | — | — | EP | disclosed |
| US-12410116-B2 | Compounds and use thereof in methods of treatment | THE UNIVERSITY OF QUEENSLAND (AU) | 2025-09-09 | — | — | US | disclosed |
| EP-4610280-A1 | METHOD FOR PRODUCING POLYPEPTIDE FROM RECOMBINANT FUSION PROTEIN AND USE THEREOF | Yangzhou Aurisco Pharmaceutical Co., Ltd (CN) | 2025-09-03 | — | — | EP | disclosed |
| US-20250223579-A1 | NOVEL CRISPR ENZYMES AND SYSTEMS | BROAD INST INC (US) | 2025-07-10 | — | — | US | disclosed |
| US-8501767-B2 | Imidazopyridines and imidazopyrimidines as HIV-1 reverse transcriptase inhibitors | CSIR (ZA) | 2013-08-06 | — | — | US | disclosed |
| US-8501767-B2 | Imidazopyridines and imidazopyrimidines as HIV-1 reverse transcriptase inhibitors | CSIR (ZA) | 2013-08-06 | — | — | US | disclosed |
| US-8501767-B2 | Imidazopyridines and imidazopyrimidines as HIV-1 reverse transcriptase inhibitors | CSIR (ZA) | 2013-08-06 | — | — | US | disclosed |
| US-20110312957-A1 | IMIDAZOPYRIDINES AND IMIDAZOPYRIMIDINES AS HIV-I REVERSE TRANSCRIPTASE INHIBITORS | CSIR (ZA) | 2011-12-22 | — | — | US | disclosed |
| US-20110312957-A1 | IMIDAZOPYRIDINES AND IMIDAZOPYRIMIDINES AS HIV-I REVERSE TRANSCRIPTASE INHIBITORS | CSIR (ZA) | 2011-12-22 | — | — | US | disclosed |
| US-20110312957-A1 | IMIDAZOPYRIDINES AND IMIDAZOPYRIMIDINES AS HIV-I REVERSE TRANSCRIPTASE INHIBITORS | CSIR (ZA) | 2011-12-22 | — | — | US | disclosed |
| EP-2334675-A1 | IMIDAZOPYRIDINES AND IMIDAZOPYRIMIDINES AS HIV-I REVERSE TRANSCRIPTASE INHIBITORS | CSIR (ZA) | 2011-06-22 | — | — | EP | disclosed |
| WO-2010032195-A1 | IMIDAZOPYRIDINES AND IMIDAZOPYRIMIDINES AS HIV-I REVERSE TRANSCRIPTASE INHIBITORS | CSIR (ZA) | 2010-03-25 | — | — | WO | disclosed |
| WO-2010032195-A1 | IMIDAZOPYRIDINES AND IMIDAZOPYRIMIDINES AS HIV-I REVERSE TRANSCRIPTASE INHIBITORS | CSIR (ZA) | 2010-03-25 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20250387582-A1 | PATIENT INTERFACE AND COMPONENT PARTS | RAE1, EXOSC9, SET | ALOX5 2804/4885BACE1 3644/4885ADORA1 2654/4885 |
| US-12552882-B2 | Polymeric disinfectants and uses thereof | PIK3C3, POLR1C, CUTA | ALOX5 754/4885BACE1 3705/4885ADORA1 2722/4885 |
| US-11697812-B2 | Methods and compositions for the specific inhibition of transthyretin (TTR) by double-stranded RNA | TTR, RNASE1, SARNP | ALOX5 4406/4885BACE1 1416/4885ADORA1 4310/4885 |
| US-20110312957-A1 | IMIDAZOPYRIDINES AND IMIDAZOPYRIMIDINES AS HIV-I REVERSE TRANSCRIPTASE INHIBITORS | TYMP, IMPDH1, DPYD | ALOX5 3673/4885BACE1 2906/4885ADORA1 1122/4885 |
| US-12410116-B2 | Compounds and use thereof in methods of treatment | SOX18, PROX1, RUNX1 | ALOX5 2213/4885BACE1 4557/4885ADORA1 4841/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.